Lixte Biotechnology Holdings, Inc. (LIXT)
| Market Cap | 41.33M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.68M |
| Shares Out | 11.17M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $3.33 |
| Previous Close | $3.32 |
| Change ($) | 0.01 |
| Change (%) | 0.30% |
| Day's Open | 3.44 |
| Day's Range | 3.22 - 3.41 |
| Day's Volume | 31,511 |
| 52-Week Range | 3.09 - 4.35 |
News
EAST SETAUKET, NY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for u...
About LIXT
Lixte Biotechnology Holdings operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active d... [Read more...]
| Industry Biotechnology | Founded 2005 |
| CEO Dr. John S. Kovach | Employees 1 |
| Stock Exchange NASDAQ | Ticker Symbol LIXT |